使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and welcome to today's DexCom first quarter year 2009 earnings conference call. Today's call is being recorded, and after opening remarks and introductions, I'd like to turn the conference over to your host, Mr. Terry Gregg.
各位好,歡迎參加 DexCom 2009 年第一季財報電話會議。今天的會議將進行錄音;在開場致詞與介紹之後,我想把會議交給本次主持人 Terry Gregg 先生。
Please go ahead.
請開始。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Thank you, operator, and welcome to DexCom's first quarter investor conference call. Joining me today on the call are Steve Pacelli, Chief Administrative Officer, and Jess Roper, Chief Financial Officer.
謝謝接線員,歡迎各位參加 DexCom 第一季投資人電話會議。今天與我一同出席的有:首席行政官 Steve Pacelli,以及財務長 Jess Roper。
The agenda will follow our normal format, with a financial review by Jess, I will provide a commercial update on our core business, a brief update on our partnerships, and we will conclude our prepared remarks and open it up to your questions. Steve will kick off with the safe-harbor statement.
議程將依照我們一貫的流程進行:先由 Jess 進行財務回顧;接著我將就核心業務提供商業面更新,並簡要更新我們的合作夥伴關係;最後結束事先準備的發言並開放提問。Steve 將先宣讀安全港聲明。
Steve?
Steve?
Steve Pacelli - CAO
Steve Pacelli - CAO
Thanks, Terry.
謝謝你,Terry。
Some of the statements that we will make in today's call may constitute forward-looking statements. These statements reflect management's expectations about future events, operating plans, and performance, and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties. A list of the factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is detailed under "Risk Factors" and elsewhere in our annual report on Form 10-K, our quarterly reports on Form 10-Q, and our other reports filed with the SEC. We undertake no obligation to update publicly or revise these forward-looking statements for any reason.
我們在今天會議中所做的部分陳述,可能構成前瞻性陳述。這些陳述反映管理層對未來事件、營運計畫與績效的預期,且僅以本日為準。這些前瞻性陳述涉及多項風險與不確定性。可能導致實際結果與任何此等前瞻性陳述所明示或暗示者存在重大差異的因素清單,已於我們的 Form 10-K 年報、Form 10-Q 季報,以及其他向 SEC 提交之報告中的「Risk Factors」及其他章節詳述。我們不承擔因任何原因公開更新或修訂這些前瞻性陳述的義務。
Terry?
Terry?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Thanks, Steve.
謝謝你,Steve。
Jess, I'll turn it over to you now.
Jess,現在我把時間交給你。
Jess Roper - CFO
Jess Roper - CFO
Thank you, Terry.
謝謝你,Terry。
Following a strong fourth quarter, DexCom continued with sequential growth during the first quarter of 2009, generating product revenue of approximately $2.7 million, compared to $1.8 million for the same quarter 2008, an increase of over 46%. Sequentially, product revenue for Q1 increased over 8% from the prior quarter.
在強勁的第四季之後,DexCom 於 2009 年第一季持續呈現季增成長,產品營收約為 270 萬美元,較 2008 年同期的 180 萬美元增加逾 46%。以季比而言,第一季產品營收較前一季成長超過 8%。
During Q1 we sold just over 1,200 systems, slightly more than we shipped during the fourth quarter of 2008. In addition, we deferred approximately $40,000 of product revenue from the sale of SEVEN systems during Q1 as we may deliver SEVEN PLUS system upgrades to certain customers who purchased the SEVEN system during the quarter. We expect to deliver these upgrades during the next couple of months and will recognize revenue when the upgrades have been delivered.
第一季我們售出略高於 1,200 套系統,略多於 2008 年第四季的出貨量。此外,由於我們可能向於本季購買 SEVEN 系統的部分客戶交付 SEVEN PLUS 系統升級,我們在第一季就 SEVEN 系統銷售遞延約 4 萬美元的產品營收。我們預期將在未來幾個月內交付這些升級,並在升級交付後認列營收。
Sequentially, sensor revenues were up 5% from the prior quarter. Total revenue for the first quarter of 2009 was $5.2 million, compared to $1.9 million for the same quarter in 2008, and included $2.5 million in development grant revenue from our development and collaboration agreements.
以季比而言,感測器營收較前一季成長 5%。2009 年第一季總營收為 520 萬美元,較 2008 年同期的 190 萬美元增加,其中包含來自我們開發與合作協議的 250 萬美元開發補助收入。
We recently amended our agreements with Edwards Life Sciences to provide that Edwards be responsible for leading and funding certain clinical study activities previously required to be performed by DexCom. As a result of this amendment, DexCom will receive $1.5 million in lower development funding from Edwards. However, the net effect is estimated to be cost neutral because DexCom no longer has the obligation to fund these clinical trial activities.
我們近期修訂與 Edwards Life Sciences 的協議,規定由 Edwards 負責主導並出資部分先前要求由 DexCom 執行的臨床研究活動。由於此項修訂,DexCom 將自 Edwards 取得的開發資金將減少 150 萬美元。然而,淨影響估計為成本中性,因為 DexCom 不再負有為這些臨床試驗活動出資的義務。
As a result of this amendment, during Q1 we recognized $2.5 million, rather than the $2.8 million, in development grant revenues as previously guided.
因此項修訂之故,我們在第一季認列的開發補助收入為 250 萬美元,而非先前指引的 280 萬美元。
Going forward beginning in Q2, we expect to recognize $2.64 million per quarter in total development grant revenue on a straight-line basis for both of our development and collaborative agreements through the end of 2010, rather than the $2.8 million that we previously guided. This quarterly estimate excludes any milestone-based payments that we may also earn. Changing the estimates could impact amounts recognized in future periods.
展望未來,自第二季起,我們預期將以直線法,在 2010 年底前,針對兩項開發與合作協議每季認列合計 264 萬美元的開發補助收入,而非先前指引的每季 280 萬美元。此每季估計不包含我們可能另行取得的任何里程碑式付款。估計變動可能影響未來期間的認列金額。
Cost of sales, including both product and nonproduct, total $5.5 million for the quarter. Product cost of sales total $3.5 million for Q1, compared to $3.1 million for the same quarter of 2008, and our product gross margin loss was $850,000 in 2009, compared to $1.3 million for the same quarter of 2008. We have experienced improvement in our negative margin primarily due to increased sales volumes in 2009.
本季銷貨成本(包含產品與非產品)合計為 550 萬美元。第一季產品銷貨成本合計為 350 萬美元,較 2008 年同期的 310 萬美元增加;2009 年產品毛利損失為 85 萬美元,較 2008 年同期的 130 萬美元改善。我們的負毛利主要因 2009 年銷售量增加而有所改善。
Development cost of sales totaled $1.95 million for the first quarter of 2009, compared to $130,000 in 2008. The increase in development cost of sales was primarily due to costs related to our development of a hospital-based continuous glucose monitoring system pursuant to our agreement with Edwards entered into during Q4 of 2008.
2009 年第一季開發銷貨成本合計為 195 萬美元,較 2008 年的 13 萬美元增加。開發銷貨成本增加主要係因我們依據於 2008 年第四季與 Edwards 簽訂之協議,開發以醫院為基礎的連續血糖監測系統所產生的相關成本。
Research and development expense decreased by approximately $1.6 million and totaled $3.2 million for the first quarter of 2009, compared to $4.8 million in 2008. It is important to note that R&D costs associated with our development and collaboration agreements with Animas and Edwards are included within development cost of sales.
研究與開發費用約減少 160 萬美元,2009 年第一季合計為 320 萬美元,較 2008 年的 480 萬美元下降。需要特別注意的是,與 Animas 與 Edwards 的開發與合作協議相關之研發成本,係列入開發銷貨成本之中。
Selling, general and administrative expense totaled $7.9 million in Q1 of 2009, compared to $6.4 million in 2008. The increase was primarily due to additional marketing, selling, and customer service-related costs. Major components of increased SG&A expense included approximately $410,000 higher salaries and $240,000 higher marketing consulting costs.
2009 年第一季銷售、一般及行政費用(SG&A)合計為 790 萬美元,較 2008 年的 640 萬美元增加。增加主要來自額外的行銷、銷售與客戶服務相關成本。SG&A 增加的主要構成包括:薪資約增加 41 萬美元,以及行銷顧問費用約增加 24 萬美元。
Sequentially, SG&A expense increased by approximately $550,000 from Q4 of 2008, primarily due to additional customer service, billing, and selling-related costs.
以季比而言,SG&A 較 2008 年第四季約增加 55 萬美元,主要由於額外的客戶服務、帳單處理與銷售相關成本。
In 2008 the Financial Accounting Standards Board issued new guidance, commonly referred to as FSP No. APB 14-1. This new guidance requires the issuer of certain convertible debt instruments to separately account for the fair value of the liability equity proponents of the instrument. The debt would be recognized at the present value of its cash flows discounted using the company's nonconvertible debt borrowing rate. The equity component would be recognized as the difference between the proceeds from the issuance of the note and the fair value of the liability.
2008 年,財務會計準則委員會(FASB)發布新指引,通常稱為 FSP No. APB 14-1。此新指引要求特定可轉換債務工具之發行人,需將該工具中負債與權益組成部分的公允價值分別入帳。債務部分應以其現金流量按公司非可轉換債務借款利率折現後的現值認列;權益部分則認列為票據發行所得款項與負債公允價值之差額。
APB 14-1 also requires the accretion or expense of the debt discount over the expected life of the debt to interest expense. The transition guides requires retrospective application to all financial periods presented.
APB 14-1 亦要求將債務折價於債務預期存續期間內攤銷(或費用化)至利息費用。過渡指引要求對所呈列之所有財務期間追溯適用。
On January 1st of 2009, we adopted the provisions of APB 14-1, which resulted in a reduction to the historical carrying value of the convertible debt on our balance sheet of $26.6 million, a reduction to the carrying value of the debt issuance cost of $1.2 million and a corresponding increase to paid-in-capital as of the issuance debt.
我們於 2009 年 1 月 1 日採用 APB 14-1 的規定,導致資產負債表上可轉換債務的歷史帳面價值減少 2,660 萬美元,債務發行成本的帳面價值減少 120 萬美元,並使實收資本相應增加(以債務發行日為基準)。
The adoption of APB 14-1 also resulted in an increase in accumulated deficit of $6.2 million and a corresponding net decrease to the carrying value of the debt discount and issuance cost as of January 1, 2009. We recorded $1.1 million and $947,000 of noncash interest expense relating to the amortization of the debt discount for Q1 of 2009 and 2008 respectively.
採用 APB 14-1 亦使累積虧損增加 620 萬美元,並使截至 2009 年 1 月 1 日之債務折價與發行成本帳面價值合計淨額相應減少。我們於 2009 年與 2008 年第一季分別認列 110 萬美元與 94.7 萬美元之非現金利息費用,係與債務折價攤銷相關。
The company also recorded $713,000 of interest expense relating to the contractual coupon payments for each of these quarters ended in March 2009 and 2008.
公司亦就截至 2009 年與 2008 年 3 月止之各季,分別認列 71.3 萬美元的利息費用,係與合約票息付款相關。
The impact of the adoption of APB 14-1 to loss per share was an additional loss of $0.02 and $0.03 per share for the quarters ended March 31, 2009, and 2008 respectively.
採用 APB 14-1 對每股虧損的影響為:截至 2009 年 3 月 31 日止季度每股額外虧損 0.02 美元;截至 2008 年 3 月 31 日止季度每股額外虧損 0.03 美元。
Going forward, we expect to record $1.2 million to $2.0 million of noncash interest expense relating to the amortization of the debt discount on a quarterly basis through March of 2012.
展望未來,我們預期將在截至 2012 年 3 月期間,按季認列與債務折價攤銷相關的 120 萬至 200 萬美元非現金利息費用。
Our net loss decrease to $13.1 million for the first quarter of 2009, compared to $13.8 million during the same quarter in 2008. Our net loss for Q1 of 2009 included $3.7 million in net noncash expenses centered primarily in share-based compensation and the expense of our convertible debt discount related to the adoption of APB 14-1, as described above.
2009 年第一季淨損失降至 1,310 萬美元,較 2008 年同期的 1,380 萬美元減少。2009 年第一季淨損失包含 370 萬美元的淨非現金費用,主要為股份基礎給付補償,以及如上所述因採用 APB 14-1 而產生之可轉換債務折價費用。
We ended the quarter with $61 million in cash and marketable securities, which excludes $3.7 million in restricted cash, and we had working capital of $51 million.
我們在本季末持有6,100萬美元的現金及有價證券(不含370萬美元的受限制現金),營運資金為5,100萬美元。
As we mentioned previously on our fourth quarter call held in March, we completed a follow-on public offering in February 2009, selling an aggregate of approximately 16 million shares of our common stock for net proceeds of approximately $45.6 million after deducting underwriting discounts, commissions, and offering expenses.
如同我們先前在3月舉行的第四季電話會議中提到的,我們於2009年2月完成一項後續公開發行,合計出售約1,600萬股普通股;在扣除承銷折扣、佣金及發行費用後,淨募集資金約為4,560萬美元。
I would like to now turn it back to our President and CEO, Terry Gregg.
我現在想把時間交還給我們的總裁兼執行長Terry Gregg。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Thanks, Jess.
謝謝,Jess。
Well, obviously, we were extremely pleased with our financial performance in the first quarter of 2009. Product revenue, new patient adds, and sensor sales were all up sequentially from Q4 2008.
很明顯地,我們對2009年第一季的財務表現感到非常滿意。產品營收、新增病患數以及感測器銷售,較2008年第四季皆呈現季增。
I'm frequently asked how is this economy impacting your business? So I'd like to take a minute to reflect on the state of the economy, its impact on the diabetes business and, specifically, our business.
我經常被問到:這樣的經濟情勢如何影響你們的業務?因此我想花一點時間回顧目前的經濟狀況、其對糖尿病產業的影響,特別是對我們業務的影響。
My years as President of MiniMed taught me that sales of durable medical equipment in the diabetes space are seasonal and are often soft in the first quarter because patients are faced with increased out-of-pocket costs as insurance deductibles are reset and because flexible spending accounts are largely unfunded. And while health care is traditionally one of the last areas in which consumers cut back on spending, there has been a slowdown in the market for certain diabetes supplies, as witnessed recently by reported lower sales in the worldwide market for SMBG products.
我在MiniMed擔任總裁的多年經驗讓我了解到,糖尿病領域的耐用醫療設備銷售具有季節性,第一季往往較疲弱,因為保險自付額重設後,病患需承擔較高的自付費用,且彈性支出帳戶多半尚未到位。雖然醫療保健傳統上是消費者最後才會削減支出的領域之一,但某些糖尿病耗材市場確實出現放緩,近期全球SMBG產品市場銷售下滑的報導即為例證。
Yet, in spite of the global economic crisis, unmet insurance deductibles, and underfunded flexible spending accounts, we delivered another quarter of sequential growth, we exceeded analyst consensus for product revenue, and, more importantly, we see a positive sales trend continuing in to the second quarter.
然而,儘管面臨全球經濟危機、尚未達成的保險自付額,以及彈性支出帳戶資金不足,我們仍交出另一個連續季增的季度表現;產品營收超越分析師一致預期;更重要的是,我們看到正向的銷售趨勢延續至第二季。
The launch of the SEVEN PLUS has been especially well received by patients and health-care providers. We believe the SEVEN PLUS is proving to be a better-performing product with noticeable performance benefits and greater ease of use for our patients. We believe the SEVEN PLUS is the only CGM system that meets the key criteria demanded by physicians, educators, and patients: convenience, performance, and simplicity.
SEVEN PLUS的上市特別受到病患與醫療照護提供者的好評。我們相信SEVEN PLUS證明是一款表現更佳的產品,具備明顯的效能優勢,且對病患而言更易使用。我們相信SEVEN PLUS是唯一符合醫師、衛教師與病患所要求關鍵標準的CGM系統:便利性、效能與簡易性。
Qualitative feedback from our field force, clinicians, and patients reinforces that product performance of the SEVEN PLUS is more reliable and consistent than ever. Product complaint rates, especially rated to -- related to sensor performance are at historically low levels, and the operational improvements we've made are resulting in substantially improved manufacturing yields and throughput.
來自我們前線團隊、臨床醫師與病患的質性回饋進一步強化了這一點:SEVEN PLUS的產品表現比以往更可靠且一致。產品客訴率,尤其是與感測器表現相關的客訴,處於歷史低點;而我們所做的營運改善也帶來顯著提升的製造良率與產能吞吐。
Since launching the SEVEN PLUS towards the end of the first quarter, our focus has been on new patients, although we hope to rapidly move to upgrading those loyal users of the SEVEN who desire to move up to the SEVEN PLUS. To that end, we are pleased to announce that just yesterday we received FDA approval to begin commercializing an upgrade kit for the SEVEN PLUS, and we expect to begin that process later this month.
自第一季末推出SEVEN PLUS以來,我們的重點一直放在新病患上;不過,我們也希望能迅速為那些希望升級至SEVEN PLUS的SEVEN忠實使用者提供升級。為此,我們很高興宣布,就在昨天我們已取得FDA核准,可開始商業化SEVEN PLUS升級套件,並預期於本月稍晚啟動該流程。
As we look to the balance of 2009, we enter what I would term a blocking-and-tackling mode of building our business. We will continue to improve our back-office systems and processing capabilities to meet expected increases in patient demand. We've made tremendous changes in terms of how our back office operates. However, we're still functioning largely on a manual basis in terms of our interaction with a payer system. We will work to move to a more automated system and expect to make progress on that front in the coming quarters.
展望2009年剩餘時間,我們將進入我所稱的「打基礎、練基本功」的業務建設模式。我們將持續改善後勤(back-office)系統與處理能力,以因應預期增加的病患需求。我們在後勤運作方式上已做出巨大改變;然而,就與付款方系統的互動而言,我們仍多半以人工方式運作。我們將努力轉向更自動化的系統,並預期在未來幾季於此方面取得進展。
We will continue to push for progress on the reimbursement front, both in terms of the adoption of new coverage policies for CGM and the establishment of contracts with payers to cover our products.
我們也將持續推動給付(reimbursement)方面的進展,包括推動CGM新承保政策的採用,以及與付款方建立合約以涵蓋我們的產品。
In summary, I remain convinced more than ever that patient demand for CGM is real and is rapidly growing, and I'm extremely pleased with our progress and momentum in the field as we work to establish continuous glucose monitoring as the standard of care for diabetes management.
總結而言,我比以往更堅信病患對CGM的需求是真實且快速成長的;同時,我也對我們在第一線推進、並致力於將連續血糖監測建立為糖尿病管理照護標準的進展與動能感到非常滿意。
We continue to make great progress in our collaboration with Edwards Life Sciences relating to the development and commercialization of a hospital-based continuous glucose monitoring system. Results of the recent NICE-SUGAR Study highlighted the continuing need to further define appropriate target glycemic levels in critically ill patients. In assessing this study, key opinion leaders continued to express the need for accurate and continuous glucose monitoring in the critical care setting.
我們與Edwards Life Sciences在開發與商業化院內使用的連續血糖監測系統方面的合作持續取得重大進展。近期NICE-SUGAR研究結果凸顯,在重症病患中仍需進一步界定適當的目標血糖範圍。在評估該研究時,關鍵意見領袖持續表達在重症照護環境中需要準確且連續的血糖監測。
Unfortunately, today there is no methodology other than utilizing traditional finger-stick measurements for monitoring glucose levels and controlling both hyper- and hypoglycemia in the hospital. Provided our development efforts in clinical studies over the next several quarters continue to demonstrate successful performance, we plan to support Edwards in seeking regulatory approval and launching our first-generation product in Europe before year end.
不幸的是,目前在醫院中,除了使用傳統指尖採血測量外,並無其他方法可用於監測血糖並控制高血糖與低血糖。若我們在未來幾季臨床研究中的開發工作持續展現成功的表現,我們計畫支持Edwards在年底前於歐洲尋求法規核准並推出我們的第一代產品。
We continue our development work on the integrated insulin pump CGM systems with our pump partners Animas Corporation and Insulet Corporation. As you might expect, coordinating the development of novel technology among multiple engineering teams can be challenging. In a slight reset of expectations, our goal is to complete all development, clinical, and regulatory efforts on these joint development projects to enable us to launch first-generation products during 2010. As you are well aware, the timing of the regulatory process is uncertain, and it is ultimately up to each of our partners to decide appropriate timing of market launch.
我們也持續與幫浦合作夥伴Animas Corporation與Insulet Corporation進行整合式胰島素幫浦CGM系統的開發。如你所預期,在多個工程團隊之間協調新技術開發可能具有挑戰性。在稍微重新調整預期後,我們的目標是完成這些共同開發專案的所有開發、臨床與法規工作,使我們能在2010年推出第一代產品。如各位所熟知,法規流程的時程具有不確定性,最終也將由各合作夥伴自行決定適當的上市時點。
To summarize, first, I am very pleased with the performance of the team at DexCom, who have functioned well under the pressures and challenges of launching the SEVEN PLUS, bringing a third-generation product in just the third year following our first product introduction.
總結來說,第一,我對DexCom團隊的表現非常滿意;他們在推出SEVEN PLUS所面臨的壓力與挑戰下運作良好,並在我們第一款產品上市後的第三年就推出第三代產品。
With our leadership role in CGM, we will continue to invest in activities to grow the category and grow our product revenues by increasing the acceptance and adoption of CGM as the best standard of care for diabetes management.
憑藉我們在CGM領域的領導地位,我們將持續投資於推動品類成長的活動,並透過提升CGM作為糖尿病管理最佳照護標準的接受度與採用率,來成長我們的產品營收。
At the core of this effort will be our focus on the patient. Daily, I aim to reinforce a patient-centric culture across the company, for I have long believed that, if you take care of the patient, everything else will take care of itself.
這項努力的核心將是我們對病患的專注。我每天都致力於在全公司強化以病患為中心的文化,因為我長期以來相信:只要照顧好病患,其他一切自然會水到渠成。
Yet, as we invest in the business, we will be ever mindful of our balance sheet. We ended the quarter with approximately $65 million in cash, marketable securities, and restricted cash, and still expect to receive up to an additional $20 million in development and milestone payments from Edwards, assuming achievement of the regulatory milestones, and an additional $5 million from Animas on receipt of a CE mark for the first OUS commercial product. If we execute on our revenue plan and we continue to spend wisely, we believe this cash will be sufficient to take us to profitability.
然而,在我們投資業務的同時,也會時刻留意資產負債表。我們在本季末持有約6,500萬美元的現金、有價證券及受限制現金;在達成法規里程碑的前提下,我們仍預期可自Edwards再收到最高額外2,000萬美元的開發與里程碑款項;此外,在第一個海外(OUS)商業產品取得CE標誌後,亦可自Animas再收到額外500萬美元。若我們能按計畫執行營收方案並持續審慎支出,我們相信這些現金將足以支撐我們達到獲利。
In the end, we are determined to ensure DexCom has the presence and staying power to drive adoption and be a meaningful participant in CGM as it evolves over time.
最終,我們決心確保DexCom具備市場能見度與長期續航力,以推動採用並在CGM隨時間演進的過程中成為重要的參與者。
Thank you.
謝謝。
Now open it up for question and answers.
現在開放提問與回答。
Operator
Operator
Thank you. (Operator instructions.) And our first question will come from Mimi Pham with JMP Securities.
謝謝。(接線員指示。)我們的第一個問題來自JMP Securities的Mimi Pham。
Mimi Pham - Analyst
Mimi Pham - Analyst
Hi. Good afternoon.
嗨,下午好。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Hi, Mimi.
嗨,Mimi。
Mimi Pham - Analyst
Mimi Pham - Analyst
Just to clarify on a timeline for the integrated pump products 2010, is J&J still expected first versus the integration with Insulet, and would you characterize as first half '10 for J&J and second half of 2010 for Insulet?
想釐清一下2010年整合式幫浦產品的時程:J&J是否仍預期會先於與Insulet的整合推出?你會不會將其描述為J&J在2010年上半年、Insulet在2010年下半年?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Mimi, that's a good question, and, unfortunately, we have been asked by our partners that -- because they really will drive the commercial introduction of these products, to defer to them, and so, in the course of that, I think that's what we need to do on this call.
Mimi,這是個好問題;但不幸的是,我們的合作夥伴要求我們——因為他們將真正主導這些產品的商業導入——把相關說法交由他們來對外,因此在這通電話會議上,我想我們需要這麼做。
Steve Pacelli - CAO
Steve Pacelli - CAO
And, Mimi, just to clarify as well, part of the reason they've been reluctant to allow us to give more specific guidance, quite frankly, is that there's a real fear on their part that patients -- if we try to zero in on specific guidance as to a market launch, that patients -- it will negatively impact their sales of their existing products. So they're not allowing us to give any more specific guidance than what we're giving you.
另外,Mimi,再補充釐清一下:坦白說,他們之所以不太願意讓我們提供更具體的指引,部分原因是他們擔心若我們試圖鎖定更明確的上市時點指引,病患可能會因此影響他們現有產品的銷售。因此,他們不允許我們提供比目前給你的更具體的指引。
Mimi Pham - Analyst
Mimi Pham - Analyst
But it sounds like the timeline still maybe took a -- is pushed back a quarter just talking about your integration timelines -- the time -- it's still pushed back -- it's at least pushed back about a quarter?
但聽起來時程可能仍然——就你們的整合時程來說——時間——仍然被往後推——至少大概往後推了一季?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Yes, I mean, Mimi, without getting into specifics, I would just say that, when these companies -- and particularly with regards to a global view of diabetes -- they have to coordinate launches not just in the US but on a global basis. And so I think, from that standpoint, it's really not as much from the developmental side or technical teams as it is as they strategize for their global, worldwide launch of products. So I would just leave it at that.
是的,我的意思是,Mimi,不談具體細節的話,我只想說,當這些公司——尤其是就糖尿病的全球觀點而言——他們必須協調的不只是美國的上市,而是全球範圍的上市。因此我認為,從這個角度來看,與其說是開發端或技術團隊的問題,不如說是他們在規劃產品的全球、全世界上市策略。就先說到這裡。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. And in terms of the impact on the economy, last quarter you had 12 patient -- 1,200 patient adds and your disposable sales were 25% this quarter. You had a little bit higher than 1,200, but you had the 5% increase sequentially in disposable rev. Do you think that there's any impact on the economy in terms of higher attrition, or anything related to that affecting your disposables revenue?
好的。那就經濟影響而言,上季你們新增了12位病患——1,200位病患新增,而你們本季的耗材銷售是25%。你們新增人數略高於1,200,但耗材營收環比只增加了5%。你認為經濟是否有任何影響,例如更高的流失率,或任何相關因素影響你們的耗材營收?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Well, I think that there's a couple things working there, and the first one is the fact that -- what we believe the impact is from the economy is that patients are using the product for a longer period of time. When we -- historically, we've said we know they use it 7 to 10 days. If we look at reorder practices, we know that they're extending that out as long as they possible can, and it's not uncommon now to see patients probably using it closer to 14 days.
嗯,我認為這裡有幾個因素在作用。第一個是——我們認為經濟帶來的影響是,病患使用產品的時間更長。過去我們一直說我們知道他們會用7到10天。如果我們看回購(reorder)行為,我們知道他們正把使用時間盡可能延長,現在看到病患可能更接近用到14天也並不罕見。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay.
好的。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Not -- it's something that we are looking at internally. We've long said that there is a mechanism to shut that sensor off, but we have chosen up to this point not to do that vis-à-vis software. Obviously, looking forward to future generations of our sensor products, we're going to have to take a much closer look at how we handle that whole shutoff process.
這——是我們內部正在觀察的事情。我們長期以來一直說有一種機制可以把感測器關閉,但截至目前我們選擇不透過軟體去做這件事。顯然,展望未來幾代的感測器產品,我們必須更仔細地檢視如何處理整個關閉流程。
Mimi Pham - Analyst
Mimi Pham - Analyst
But it doesn't seem like -- it sounds like you're not seeing higher attrition, you're just seeing people use the sensors longer?
但看起來不像是——聽起來你們沒有看到更高的流失,而只是看到人們把感測器用得更久?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
It is difficult to say. I would generally make a comment that, no, we don't see a higher attrition rate. We're seeing, as we move more to reimbursement, certainly the -- if you look at the average number of boxes of sensors sold per order, that is increasing due to the reimbursement. So as we move to a higher reimbursement, we're allowed to ship more boxes. So coming out of the first quarter, as an example -- or coming out of the fourth quarter '08, as we had a particularly strong December, if we were able to ship more than one or two boxes, obviously, and they're extending the use of that, we're going to see a little dampening, as we've expressed, in this -- the first quarter. But, again, that should turn itself around as they go to reorder under these insurance contracts.
這很難說。我一般會評論說,不,我們沒有看到更高的流失率。隨著我們更多轉向報銷(reimbursement),當然——如果你看每筆訂單平均售出的感測器盒數,因為報銷的關係那是在增加的。所以當我們走向更高的報銷水準時,我們被允許出貨更多盒。舉例來說,從第一季出來——或從2008年第四季出來,因為我們12月特別強勁,如果我們能出貨超過一到兩盒,顯然,而且他們又延長使用時間,我們就會在——如我們所說——第一季看到一些抑制效應。但同樣地,當他們在這些保險合約下進行回購時,這應該會自行回轉。
Mimi Pham - Analyst
Mimi Pham - Analyst
Thank you. And then last question, for your SEVEN PLUS, is there a pricing premium for the starter kit, and did you talk about the price for the upgrades?
謝謝。那最後一個問題,關於你們的SEVEN PLUS,入門套件是否有溢價定價?你們有談到升級的價格嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
We do have --
我們確實有——
Steve Pacelli - CAO
Steve Pacelli - CAO
Yes, I mean, Mimi, yes, there is a pricing increase. Again, there's a current cash promotion. I believe that price is $799 for the durable system. But keep in mind, as we've moved to a reimbursed environment, pricing, I would tell you, is kind of all over the map. What we've disclosed previously is that our ASP has certainly migrated north from the -- what we were seeing the $600 range to closer to a $700 ASP from a reimbursed perspective. But it's kind of hard to say, yes -- so, yes, we do have an increased price on the SEVEN PLUS, but I would tell you that that doesn't really have a direct link to pricing that we receive from our insurance contracts. Does that make sense?
是的,我的意思是,Mimi,是的,確實有漲價。同樣地,目前有現金促銷。我相信耐用系統(durable system)的價格是799美元。但請記住,隨著我們轉向可報銷的環境,定價我會告訴你,某種程度上是到處都有。先前我們揭露過的是,從報銷角度來看,我們的ASP確實已經往上移動——從我們看到約600美元的區間,移到更接近700美元的ASP。但很難說,是的——所以,是的,SEVEN PLUS的價格有提高,但我會告訴你,這與我們從保險合約收到的定價其實沒有直接連結。這樣說有道理嗎?
Mimi Pham - Analyst
Mimi Pham - Analyst
Yes. Yes, it makes sense. And then -- that makes sense.
有。有道理。然後——是的,這樣說有道理。
Steve Pacelli - CAO
Steve Pacelli - CAO
Yes, and then we will launch an upgrade, and the price for the upgrade for users of the SEVEN who are still under warranty -- so they have to be within their one-year warranty period -- would be able to upgrade for $199.
是的,然後我們會推出升級方案,對於仍在保固期內的SEVEN使用者——也就是必須在一年保固期內——可以用199美元進行升級。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. Thank you so much.
好的。非常感謝。
Operator
Operator
And our next question will come from Ben Andrew with William Blair.
下一個問題來自William Blair的Ben Andrew。
Ben Andrew - Analyst
Ben Andrew - Analyst
Good afternoon, guys.
各位下午好。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Hey, Ben.
嗨,Ben。
Ben Andrew - Analyst
Ben Andrew - Analyst
Just a few questions. What all is included in the SEVEN PLUS upgrade kit? Is it just the new durable, or is there new software or anything else that the patient needs, and is there any kind of constraints on availability of those?
幾個問題。SEVEN PLUS升級套件包含哪些內容?只是新的耐用設備(durable)嗎,還是有新的軟體或病患需要的其他東西?另外供應上是否有任何限制?
Steve Pacelli - CAO
Steve Pacelli - CAO
Yes, no availability constraints but the -- it actually includes a new transmitter, and it'll include software that the patient will actually upgrade the firmware. So they don't actually have to swap out the receiver. We replace the firmware within the existing SEVEN receiver, but they do require -- the system does require a new transmitter.
是的,沒有供應限制,但——它其實包含一個新的發射器(transmitter),也會包含軟體,讓病患實際去升級韌體(firmware)。所以他們其實不需要更換接收器(receiver)。我們是在既有的SEVEN接收器裡替換韌體,但系統確實需要一個新的發射器。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. And, Terry, as you think about reimbursement -- and maybe Steve as well -- what chunk of your patients have a material copay? How -- what chunk are HMO's -- maybe they do only have a $10 copay -- versus (inaudible) in PPO and maybe higher so -- to try to understand better the constraints on patients' willingness to pay the copay on both the sensor as well as the upgrade?
好的。那,Terry,當你思考報銷——也許Steve也可以——你們的病患中有多少比例需要支付實質的自付額(copay)?有多少比例是HMO——可能只要10美元自付——相對於(聽不清)在PPO裡可能更高——想更好理解病患在感測器以及升級上支付自付額的意願所受到的限制?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Yes, no, Ben, we have not stratified that information. I'm sure it's within the bowels of our system if we could stratify it but I'd -- I'll remind you of my earlier comment with regards to we're still basically a manual-processing unit brute-forcing some of this stuff until we finish our software upgrades in that particular area and be able to extract that information.
是的,沒有,Ben,我們沒有把那個資訊分層(stratify)。我確定如果能分層的話,它在我們系統的深處是有的,但我——我提醒你我先前的評論:我們基本上仍是一個手動處理單位,在完成該領域的軟體升級、並能夠擷取那些資訊之前,我們只能用比較原始的人工作業方式去硬做其中一些事情。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. So then maybe following on that, as you try to go to automatic with these accounts and the payers, what does that really take? Does it take a contract with each local payer, or is it software? I mean, how difficult and time-consuming is that going be, you said, quarters?
好的。那接著問,當你們試著讓這些帳戶與付款方走向自動化時,實際上需要做什麼?是需要和每個地方性的付款方各自簽合約,還是主要是軟體?我的意思是,這會有多難、多耗時?你說是以季為單位?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Well, it's certainly going to be time-consuming from a standpoint that, while we're converting this over we're -- our ERP system is an Oracle-based ERP system so we've got to integrate with ERP system at the same time to sign up contracts and allow that electronic communication to them. Obviously, all of that requires B&B confirmation. So there's a lot of handholding that goes on. In the meantime, we still need to process patients on an ongoing basis. So it is a major undertaking. We have completed the first of probably four steps to that that is live as of this month, and so we've got an additional three, what I call, modules that need to be activated. That's going to take most of the rest of the year to do that.
嗯,這肯定會很耗時,因為在我們把它轉換過來的同時——我們的ERP系統是以Oracle為基礎的ERP,所以我們必須同時與ERP系統整合,並簽訂合約,讓與他們之間的電子通訊得以進行。顯然,這一切都需要B&B確認。因此有很多需要手把手協助的工作。同時,我們仍需要持續處理病患。因此這是一項重大工程。我們已完成大概四個步驟中的第一步,並在本月上線,所以我們還有另外三個我所謂的模組需要啟用。這將花掉今年剩下的大部分時間來完成。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. And then shifting gears, Terry, why the change in the Edwards contract? Was it just logistics or some other reason?
好的。那換個話題,Terry,為什麼要更改與Edwards的合約?只是物流因素還是其他原因?
Steve Pacelli - CAO
Steve Pacelli - CAO
No, Ben, quite honestly, the -- so the only change is that Edwards has agreed to take on the responsibility for a portion of the clinical trials, and, quite frankly, it goes to the heart of why we did this deal with Edwards in the first place, which is we're not experts in the critical-care setting. And it became clear through the beginnings of the -- of developing the protocols, etc., for the pivotal trial that Edwards would be in a much better position to interact with folks that they're used to interacting with in terms of getting patients enrolled and consented to the clinical trials, working with the critical-care centers, as opposed to the types of sites that we use for our ambulatory product. So it -- over the course of this development, it just became clear that it would be much better served if Edwards took the responsibility of this trial. And all we did is just basically took away the estimated amount we would spend that they were going to fund for us to conduct the trial, deducted that from what they would be paying us, so they're going to have -- they'll fund it and run it themselves.
不,Ben,老實說——所以唯一的改變是Edwards同意承擔部分臨床試驗的責任。坦白說,這回到我們一開始和Edwards做這筆交易的核心原因:我們不是重症照護(critical-care)場域的專家。在為關鍵性試驗(pivotal trial)制定方案等工作的初期就很清楚,Edwards在與他們熟悉的對象互動方面會更有優勢,包括讓病患入組並取得臨床試驗同意、與重症照護中心合作;相較之下,我們用於門診(ambulatory)產品的試驗機構類型不同。因此——在這個開發過程中,越來越清楚由Edwards來負責這項試驗會更合適。我們所做的只是把我們原本預估會花、而他們原本要資助我們用來執行試驗的金額,從他們要付給我們的款項中扣除;所以他們將自行出資並自行執行。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
And we've been -- it's been a great relationship. They actually have people here in San Diego on our campus shoulder to shoulder. We have trained them as we move in to the first protocol. So they are completely capable of running the trials in the ICU and in the clinical setting. They've got a lot more horsepower in order to do that in terms of their staff than we do. We were spread pretty thin going in to this. So I think it's -- for us it -- we had offered that up as part of the original contract, and they have taken us up on our offer. So we're thrilled with it.
而且我們一直——這一直是很棒的合作關係。他們其實有人在聖地牙哥、就在我們園區裡與我們並肩作戰。我們在推進到第一個試驗方案時已經訓練了他們。所以他們完全有能力在加護病房(ICU)以及臨床環境中執行試驗。就人力配置而言,他們在這方面的能量比我們大得多。我們在投入這件事時人手其實相當吃緊。所以我想——對我們來說——我們在原始合約的一部分就提出了這項支援,而他們也接受了我們的提議。所以我們對此非常興奮。
Ben Andrew - Analyst
Ben Andrew - Analyst
Great. And then last question, Steve -- or I guess maybe a question for Jess really -- if you look at gross margin, it was a bit -- quite a bit better on the product side than I expected, which is great to see. How do you anticipate that margin progressing through the year? Are you -- do you think you can make significant progress as a percent to revenues over the course of the year?
很好。那最後一個問題,Steve——或者我想其實是問 Jess 的——如果看毛利率,產品端比我預期的要好一些——其實好不少——很高興看到這點。你們預期這個毛利率在今年會如何演進?你們——你覺得在今年的過程中,毛利率占營收的百分比能有顯著改善嗎?
Jess Roper - CFO
Jess Roper - CFO
Well, we don't really give too much guidance, but I think, if you look back historically quarter to quarter in 2008 and then Q1 of 2009 on the product cost of sales, we really haven't had much of an uptick, and most of -- a lot of our costs are really kind of factory overhead costs, and we've been able to, just through sales volume, get a lower cost per unit. We're kind of chewing the overhead costs. So we hope that product cost of sales don't go up that high. Again, we said we had excess capacity issues in the past.
嗯,我們不太提供太多指引,但我想,如果你回頭看 2008 年逐季以及 2009 年第一季的產品銷貨成本,我們其實沒有看到太多上升,而且我們的成本中——很大一部分——其實是工廠製造間接費用(overhead),而我們能夠透過銷售量的提升,把每單位成本降下來。我們算是在消化這些間接費用。所以我們希望產品銷貨成本不要上升太多。再說一次,我們之前也提過我們過去有產能過剩的問題。
Steve Pacelli - CAO
Steve Pacelli - CAO
And, as Terry mentioned, Ben, in his statements, we are working on some process improvements, manufacturing improvements that are providing us with just better yields, less scrap, just kind of all the things that you would expect to do as we mature as a business to help drive those costs down.
另外,如 Terry 在他的發言中提到的,Ben,我們正在推動一些製程改善、製造改善,讓我們有更好的良率、更少的報廢,基本上就是你會期待一家企業在成熟過程中會做的那些事,來幫助把成本往下拉。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. So that can stay relatively stable. Maybe there's some quarterly fluctuations there.
了解。所以那可以維持相對穩定。也許會有一些季度間的波動。
Steve Pacelli - CAO
Steve Pacelli - CAO
Yes, I think that's right. I mean, we would expect it to improve on a quarterly basis, certainly, without giving specific guidance as to when we would -- I think the guidance we've given previously is that we would expect in a quarter of a $5 million product revenue quarter that we would be gross margin positive.
是的,我想沒錯。我的意思是,我們確實預期它會逐季改善,當然不提供何時會——的具體指引。我想我們先前給過的指引是:我們預期在單季產品營收達到 500 萬美元的季度,我們的毛利率會轉正。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. Okay. Great. Thank you.
好。好。很好。謝謝。
Operator
Operator
We'll move on to Thom Gunderson with Piper Jaffray.
我們接著請 Piper Jaffray 的 Thom Gunderson。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
Hi. Let me just do some quick cleanup. Jess, could you repeat what you said on deferrals? I didn't catch the number.
嗨。我先快速做幾個釐清。Jess,你可以重複一下你剛剛關於遞延(deferred)的說法嗎?我沒聽到那個數字。
Jess Roper - CFO
Jess Roper - CFO
On the deferred revenue piece?
你是指遞延收入那一塊嗎?
Thom Gunderson - Analyst
Thom Gunderson - Analyst
Right.
對。
Jess Roper - CFO
Jess Roper - CFO
Yes, we deferred approximately $40,000 in deferred revenue related to the upgrade to the SEVEN PLUS system and --
是的,我們就與升級到 SEVEN PLUS 系統相關的部分,遞延了大約 4 萬美元的遞延收入,並且——
Thom Gunderson - Analyst
Thom Gunderson - Analyst
Got it. Got it.
了解。了解。
Jess Roper - CFO
Jess Roper - CFO
-- we expect those upgrades in the next couple of months.
——我們預期這些升級會在接下來幾個月內完成。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
Thanks. And then is it fair to assume -- you said 1,200 systems were sold. Is that fair to assume that that's all new customers?
謝謝。那接著,這樣理解是否合理——你說賣出了 1,200 套系統。是否可以合理假設那全部都是新客戶?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Yes, I mean, at this point, it would be all new customers. I'd have to go back, Thom, and specifically look at that, but that's not part of an upgrade program.
是的,我的意思是,就目前來看會是全部都是新客戶。我得回去,Thom,特別確認一下,但那不是升級方案的一部分。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
Okay. And then, realizing that there is all sorts of inputs in to how you launch a product and certainly how you launch a product when you're working with a partner -- some of them larger, some of them smaller -- can you comment, Terry, just a little bit on your own internal timelines. Have your internal timelines changed on Animas or Edwards or Insulet faster or slower in the last three to six months?
好。然後,考量到產品上市的方式有各種投入因素,尤其是你們與合作夥伴一起推產品——有些規模較大、有些較小——你能不能,Terry,稍微談一下你們內部自己的時程?在過去三到六個月,你們對 Animas 或 Edwards 或 Insulet 的內部時程,有變快或變慢嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
No, not really. I think one of the challenges in any of these, and I would say -- let's take Edwards as an example because we're teaching them through this process, and they're here on campus, they're within our R&D environment, and that one has gone, I think, quite swimmingly well, and, in fact, we're right on schedule for everything -- both parties -- so we're pretty happy about that.
沒有,沒有太大改變。我想這類事情的一個挑戰是——我會說——以 Edwards 為例,因為我們正透過這個流程在教他們,他們也在園區裡、就在我們的研發環境中;我認為那個案子進展得相當順利,事實上,我們在所有事項上——雙方——都完全按進度進行,所以我們對此很滿意。
If you look at the other two in the (inaudible), it's integrating our product into their platform, and so it's a different animal from that standpoint, Thom, and we have -- we rely on their engineering staff to a great degree because, ultimately, no matter what we do -- remember, we embed our software into their hardware and so it's -- in many cases you have a different landscape that you're trying to work through and relying on their engineering staff to bear a good portion of the burden as we work through these issues. So it's a little bit different.
如果你看另外兩個在(聽不清)裡的案子,那是把我們的產品整合到他們的平台上,所以從這個角度來看是不同的情況,Thom。我們在很大程度上依賴他們的工程團隊,因為最終不管我們做什麼——記得,我們是把軟體嵌入到他們的硬體裡——所以在很多情況下,你面對的是不同的環境,需要一路摸索並且依賴他們的工程團隊在我們處理這些問題時承擔相當一部分的工作量。所以會有點不一樣。
But, no, I think these things at -- as we've expressed them, once they get outside of our complete control, we don't always have the visibility, I think, that we would necessarily have if they were completely in our control.
但沒有,我想這些事情——如同我們所表達的——一旦超出我們完全可控的範圍,我們不一定總能有我們希望擁有的能見度;如果它們完全在我們控制之下,我想我們本來會有更高的可視性。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
Okay. But just to try and put words in your mouth -- never successful, but I'll try -- is -- you knew that, having DexCom on board for other companies -- the software into hardware -- you knew that challenge from the get-go, and you put timelines together, and you've been working diligently towards that. Those timelines haven't changed.
了解。不過我試著把話塞到你嘴裡——通常不會成功,但我試試——也就是——你一開始就知道,讓 DexCom 與其他公司合作——把軟體放進硬體——從一開始就知道這個挑戰,然後你們訂了時程並且一直努力推進。那些時程並沒有改變。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Yes, I would say in the global sense, no, they haven't really changed. I think some factors have come in to play that we didn't necessarily anticipate. When you look at the global business of launching a product, I think, our thought process -- because at the time we entered into these -- was simply, look, we're going to get stuff going in the US. We didn't -- as a stand-alone, we did not at that time have a product that we planned to introduce OUS. Now we subsequently this year signed an extension of our contract with Animas for OUS, and they want to launch that. They now have, I think, more thoughtfulness going forward as to what it looks like for them in a global launch with their distribution system. So there's just more factors at play. They have to seek more counsel from a strategy-wise in terms of commercial introduction. It's not just US. And in the J&J world, obviously, that requires a lot more discussion at senior levels.
是的,我會說就整體而言,沒有,並沒有真正改變。不過我想有一些因素出現,是我們未必事先預期到的。當你看產品上市的整體業務面時,我想我們當時的思路——因為在我們簽這些合作時——很單純:看,我們會先在美國把事情做起來。當時我們作為一家獨立公司,並沒有一個計畫要在美國以外(OUS)推出的產品。現在我們在今年稍後與 Animas 簽了合約延伸,涵蓋 OUS,而他們希望在那裡上市。他們現在在往前看時,對於透過他們的通路系統進行全球上市會是什麼樣子,我想有更多的深思熟慮。所以就有更多因素在起作用。他們在商業導入的策略面需要尋求更多建議。這不只是美國。而在 J&J 的體系裡,顯然這需要在更高層級進行更多討論。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
And then last question is you covered the economy and the economy and diabetes and the economy and DexCom well. I guess I would just ask you, from your standpoint, when you do that well swimming upstream in a tough economy, did you feel the current running against you? Were there anecdotes out there? Were there current customers that were -- that you heard about that were struggling, or was it just full speed ahead because you're so early on the adoption curve that you didn't feel it?
那最後一個問題是,你把經濟、經濟與糖尿病、以及經濟與 DexCom 的關係講得很清楚。我想我只是想問,從你們的角度,當你們在艱困的經濟環境中仍能逆勢表現得這麼好時,你有感覺到逆流在阻礙你們嗎?有沒有一些軼事?有沒有現有客戶——你們聽到他們在掙扎?還是說因為你們仍在採用曲線的很早期,所以沒有感受到影響,一切仍是全速前進?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
It's the latter. I mean, we have felt no real headwinds to speak of. If anything, it's been tailwinds. The demand -- I mean, our pipeline, as I look today down in the sales operations, the back office, we are full, processing as rapidly as we can possibly process. We've got efficiency experts on staff right now and consultants -- as part of what Jess was talking about -- to look at how we process more, rather than less. So -- and my comment about going in April -- April was the first month after a strong quarter, again, I always get nervous, but there was no letdown from day one. So I don't see it yet.
是後者。我的意思是,我們幾乎沒有感受到任何所謂的逆風。若真要說,反而是順風。需求——我的意思是,今天我去看銷售營運、後勤辦公室那邊的管線,我們是滿載的,正以我們所能的最快速度在處理。我們現在有流程效率專家與顧問——就像 Jess 剛剛提到的——在看我們如何能處理更多,而不是更少。所以——而我提到四月——四月是在一個強勁季度之後的第一個月,我一向會緊張,但從第一天起就沒有任何降溫。所以我目前還沒看到。
What I do see -- and, again, it gets back to this issue with regards we do, anecdotally, hear more and more patients talking about the extension of use of the product beyond its recommended use, and the SEVEN PLUS with the new algorithm -- more data capture -- has only exacerbated their capacity to do that. And so we have to think about that going forward to next generation.
我確實看到的是——而且再一次,這回到我們所做的這件事——我們在軼事上聽到越來越多病患在談,他們把產品的使用時間延長到超過建議使用期限;而 SEVEN PLUS 搭配新演算法——更多資料擷取——只會讓他們更有能力這麼做。所以我們必須在往下一代產品時把這點納入考量。
I mean, Thom, our long-term goal -- and I think anybody in the category -- is to clearly get to a point where we are sophisticated enough, accurate enough to have insulin dosing off of ISF glucose. We believe that at some point we can get there, and we believe we'll be the first to get there. That may be the time that we do different things in order to really -- and from an FDA standpoint, we want that labeled indication -- we may have to have more restriction on terms of how the sensor can be used and for how long. But until we actually get to a point where we want to make out an application to FDA, I think we're not going to change that. But that's kind of the behavior, if anything, from the patient standpoint.
我的意思是,Thom,我們的長期目標——我想同類別的任何人都是——是明確地達到一個程度:我們足夠成熟、足夠精準,能夠根據 ISF 的葡萄糖數據來進行胰島素劑量調整。我們相信在某個時間點我們可以做到,而且我們相信我們會是第一個做到的。到了那個時候,為了真正——從 FDA 的角度來看,我們希望取得那個標示適應症——我們可能必須在感測器如何使用以及可使用多久等方面施加更多限制。但在我們實際走到要向 FDA 提出申請的那一步之前,我認為我們不會改變這一點。不過,從病患的角度來看,這大概就是(如果有的話)他們的行為。
And the ease in which they can restart it. I mean, just go to YouTube, and you can have a full display of how to do that. It's very convenient for the patient. Where, if I made any mistake in terms of understanding the patient dynamic, I really thought that, once reimbursement was here, there would be less motivation on the part of the patients to stretch the use out beyond seven, eight, nine days, and I calculated wrong. Patient -- I did not take into consideration the ease of use, the simplicity of use, or the convenience the patients like that they simply just restart it because they then don't have to go through the entire application and startup process. So that's just the area where, I think, if we possibly had it to do over again, we may have done something differently. I can't say that for sure because at novel adoption there is quite a marketing cache to know that we are the most durable, certainly the most accurate in hypoglycemia detection, the most convenient, the simplest to use. I mean, all of those things, given the commercial mass of our competitors, are really great things to have in trying to compete in that environment.
以及他們重新啟動它的容易程度。我的意思是,你只要上 YouTube,就能看到完整示範如何操作。對病患來說非常方便。若說我在理解病患動態上有什麼誤判,我原本真的以為一旦有了給付,病患就比較沒有動機把使用時間拉長到超過七、八、九天,但我算錯了。我沒有把易用性、操作的簡單性,或病患喜歡的便利性納入考量——他們只要重新啟動,就不必走完整的安裝與啟動流程。所以這就是我認為如果能重來一次,我們可能會做得不一樣的地方。我也不能百分之百確定,因為在新產品採用初期,能夠讓市場知道我們最耐用、在低血糖偵測上當然也最精準、最方便、最簡單易用,這些都有相當的行銷加分。我的意思是,考量到競爭對手的商業規模,擁有這些優勢在那樣的競爭環境中真的很有幫助。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
Okay. Thanks, Terry.
好的。謝謝你,Terry。
Operator
Operator
And our next question will come from Bill Plovanic with Canaccord Adams.
下一個問題來自 Canaccord Adams 的 Bill Plovanic。
Anoop - Analyst
Anoop - Analyst
Good afternoon. This is actually Anoop for Bill.
午安。其實我是代 Bill 的 Anoop。
A lot of the questions have been asked. Couple of follow-ups. In terms of UNH, is there any update in the pricing contracts with UNH?
很多問題都已經問過了。我有幾個追問。關於 UNH,與 UNH 的定價合約有任何更新嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
I'll let Steve answer.
我讓 Steve 來回答。
Steve Pacelli - CAO
Steve Pacelli - CAO
Yes, no, we're still -- Anoop, we're still working on that. Just to give you a sense of where we are, United is a little bit different compared to some of the other payers in the sense that United has adopted a policy of preferring to actually cause us to work through a distributor. And the reason they do that is because United has -- they believe, I think, have greater purchasing power working through a single entity where they can purchase not just CGM supplies from us but purchase strips, insulin, etc. So the -- this is going to take a little longer than, I think, we initially expected because we've got to basically prove to United that they would be much better off economically working directly with DexCom.
是的,沒有,我們仍然——Anoop,我們還在處理這件事。讓我說明一下目前的狀況:United 跟其他一些付款方有點不同,因為 United 採取的政策是偏好讓我們透過經銷商來合作。他們這麼做的原因是,United——我想他們相信——透過單一實體來運作會有更大的採購力,因為他們不只可以向我們採購 CGM 耗材,還可以採購試紙、胰島素等等。所以——這件事會比我們一開始預期的花更久時間,因為我們基本上得向 United 證明:直接與 DexCom 合作在經濟上會更划算。
Now, that said, it's important to remember we do have access to the United network via one of our DME -- actually multiple DME suppliers. So the fact and the absence that we don't have a direct contract really is nothing more than a potential to improve some margin on the United -- the sales to United patients. But we do have access to that network so it's not like -- excuse me -- that we're precluded from transacting with those patients on a reimburse basis.
不過話說回來,重要的是要記得:我們確實透過我們的 DME——其實是多家 DME 供應商——可以進入 United 的網路。因此,沒有直接合約這件事,實際上只是意味著我們在對 United 病患的銷售上,有機會改善一些毛利。但我們確實能接觸到那個網路,所以並不是——不好意思——我們被排除在外,無法以給付的方式與那些病患進行交易。
Anoop - Analyst
Anoop - Analyst
And then it's safe to say that UNH was beneficial in the quarter and is likely to continue to be --
那麼可以說 UNH 在本季是有幫助的,而且很可能會持續——
Steve Pacelli - CAO
Steve Pacelli - CAO
Absolutely.
絕對是。
Anoop - Analyst
Anoop - Analyst
Okay. And then could you just explain one more time the pricing premium on the SEVEN PLUS? I just missed some of the explanation on that.
好的。那你能不能再解釋一次 SEVEN PLUS 的定價溢價?我剛剛漏聽了一些說明。
Steve Pacelli - CAO
Steve Pacelli - CAO
Sure. Let me try to be more clear. So let's talk about the upgrade first. So we'll offer to users of the SEVEN who are still within their one-year warranty period, they will have the right to purchase an upgrade to the SEVEN PLUS for $199, and that upgrade will include a firmware upgrade to their existing receive, and it will include a new transmitter. Okay? So that's the upgrade kit.
當然。我再講清楚一點。先談升級。對於仍在一年保固期內的 SEVEN 使用者,我們會提供他們以 199 美元購買升級到 SEVEN PLUS 的權利;這個升級會包含對其現有接收器的韌體升級,並且包含一個新的發射器。好嗎?這就是升級套件。
Now, for new SEVEN PLUS kits, we're currently running a cash -- for nonreimbursed patients a cash promotional price of $799 for the SEVEN PLUS system. Okay?
接著,對於新的 SEVEN PLUS 套組,我們目前對未獲給付的病患提供現金促銷價:SEVEN PLUS 系統 799 美元。好嗎?
We will also establish -- we have not disclosed -- we do have a new, what I'll call, a list price, which we have not disclosed yet. But what I tried to make clear -- and I'll try it again in case it wasn't clear -- is that that list price doesn't really have a direct impact on our ASP because, remember, we have -- now have negotiated contracts with -- either through a DME supplier or on a direct basis with virtually all of the insurance payers that we do business with. And the pricing, I would say, it's all over the map. I mean, it's -- we have indicated that our ASP's -- historical ASP's have gone up. So that tells you that the pricing, certainly across the payers, is better than we were seeing on our historical cash basis.
我們也會建立——我們尚未揭露——一個新的、我稱之為牌價(list price)的價格,目前還沒有對外公布。但我想要講清楚——如果剛剛不夠清楚我再說一次——那個牌價其實不會直接影響我們的 ASP,因為請記得,我們現在——不論是透過 DME 供應商或直接合作——已經與幾乎所有我們往來的保險付款方談妥合約。而定價我會說差異很大,真的各式各樣。我們也已經指出,我們的 ASP——歷史 ASP——是上升的。所以這告訴你,至少在各付款方之間的定價,確實比我們過去以現金為主的歷史水準更好。
But to be able to tell you exactly what our pricing is on the SEVEN PLUS is sort of a tough thing. I think, as we get clarity down the road on our ASP's -- we've been pretty good about kind of giving you a good sense of what our ASP is on both the durables and the sensors, and so what we're saying today is that our ASP has moved up closer to $700, as opposed to $600, where it was historically on a cash basis, and that our sensor ASP is moving north of $60. We haven't been more specific than that at this point.
但要我精確告訴你 SEVEN PLUS 的定價到底是多少,某種程度上很難。我想,隨著未來我們的 ASP 更明朗——我們一直都很擅長讓大家大致掌握耐用品與感測器的 ASP——所以我們今天要說的是:我們的 ASP 已經往上移,接近 700 美元,而不是過去現金銷售歷史上的 600 美元;而我們的感測器 ASP 也正在往 60 美元以上走。到目前為止我們還沒有更具體。
Does that clarify it at all?
這樣有比較清楚嗎?
Anoop - Analyst
Anoop - Analyst
Yes, it does. Thank you. And that's it. Thank you.
有的,清楚了。謝謝。就這些了。謝謝。
Operator
Operator
(Operator instructions.) And next we'll hear from Shawn Fitz with Stephens, Inc.
(接線生指示。)接下來我們將聽取 Stephens, Inc. 的 Shawn Fitz 提問。
Shawn Fitz - Analyst
Shawn Fitz - Analyst
Good afternoon. Terry, this probably dovetails a little bit with some of your commentary as it relates to demand and the economy. Are you currently experiencing constraints on your ability to add new patients as a result of some of your back-office capacity issues?
午安。Terry,這可能和你先前關於需求與經濟的評論有點呼應。你們目前是否因為後勤(back-office)產能的一些問題,而在新增病患的能力上受到限制?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
The answer -- easy answer is no. We certainly are strained from that standpoint, but if you remember back a couple quarters, we really got caught flat-footed, Shawn, in that third quarter of '08 when we had a lot more in queue than we were able to process. We are keeping up at this point, but we are having to manually force that through. So that means there's overtime, there's other ways in which we're addressing this. It is a challenge. I do not want to minimize the challenge.
答案——簡單的答案是否。我們在那方面確實很吃緊,但如果你回想幾個季度前,Shawn,我們在 2008 年第三季確實有點措手不及,因為排隊等待處理的量遠超過我們能處理的量。目前我們是跟得上的,但我們必須用人工方式硬把流程推過去。這代表需要加班,以及用其他方式來因應。這是一個挑戰。我不想淡化這個挑戰。
Luckily for us that a couple of the major payers have in many ways adjusted their requirements, and so as a result of that, we need less documentation, which means more expeditious processing of the claims. So that has lessened some of the load, and they're some of the major players from that standpoint.
對我們來說幸運的是,有幾家主要付款方在很多方面調整了他們的要求,因此我們需要的文件變少了,這也意味著理賠處理可以更快速。這減輕了一部分負荷,而這些付款方在這方面都是主要玩家。
But we need to continue to streamline, and that's why, if you look at what the field -- I asked the field force to do something, they have performed extraordinarily well, and I think our -- if you look at what our ratio is, we're still -- we have a lot of MDI patients so this has been an opportunity. We have to remind people that the world of diabetes is only roughly approaching 30% pump penetration but still north of 50% MDI, and so we have gone out and -- we still have a good ratio of MDI patients versus our pump patients.
但我們仍需要持續精簡流程;這也是為什麼,如果你看前線——我請前線團隊做一些事情,他們表現得非常出色。我想我們——如果你看我們的比例,我們仍然——我們有很多 MDI 病患,所以這一直是個機會。我們必須提醒大家,糖尿病領域胰島素幫浦的滲透率大約才接近 30%,但 MDI 仍然超過 50%;因此我們走出去——我們在 MDI 病患相對於幫浦病患方面,仍然維持不錯的比例。
But that said, they continue to amaze me in their ability to fill the channel. And, in fact, some of our -- if you look at our -- the S portion of our SG&A -- and I'm happy to report we were overbudget in terms of the commissions. I'm happy to pay commissions when guys overachieve -- and the gals. So they're doing their part. Our obligation -- we are their customer in the back office, and we're able to keep up.
不過話說回來,他們在填滿通路方面的能力仍然讓我驚豔。而且,事實上,如果你看我們的——如果你看我們的——SG&A 裡面的 S 部分——我很高興可以報告,就佣金而言我們是超出預算的。我很樂意在大家——還有女士們——表現超標時支付佣金。所以他們正在盡他們的本分。我們的責任——我們在後勤辦公室是他們的客戶,而我們也能跟得上。
Shawn Fitz - Analyst
Shawn Fitz - Analyst
Okay. Okay. Great, Terry. And then you spoke a little bit about the improvements you all have been able to gain on the yield side of manufacturing. Terry, could you maybe quantify how much room there still is to improve yields, or are you guys kind of fully meeting your objectives on a yield standpoint?
好的。好的。很棒,Terry。接著你稍微談到你們在製造端良率方面所取得的改善。Terry,你能不能量化一下良率還有多少改善空間?還是你們在良率目標上基本上已經達標了?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Well, I would say from a standpoint of where we're at on yields, we're pretty happy with where we have improved and -- from the last couple of quarters and the guys -- I think no one will ever be entirely happy from a standpoint. We have -- based on what we had projected where we would be at at the end of the first quarter on the yield category, we have overachieved on that, and that results in some of the improvements that Jess reported on. We need to continue to do that.
嗯,我會說就我們目前的良率而言,我們對過去幾季的改善——以及團隊——相當滿意。我想從某個角度來看,沒有人會完全滿足。我們——以我們原先預估第一季末在良率類別應達到的水準來看,我們已經超額達成,而這也帶來 Jess 所報告的一些改善。我們需要持續這麼做。
I think the -- well, the bigger issue, the bigger opportunity -- as I've said before, we have plenty of capacity here given 2009. Obviously, some of the things that we've got planned for manufacturing improvements are not just the yields. It's really as it relates to the ability to process much greater quantities. And I've talked about that historically in terms of our gen-four product, which is moving along quite nicely in the R&D environment and moving now in to some areas of the production facility.
我認為——嗯,更大的議題、更大的機會——如我之前所說,考量 2009 年,我們這裡有充足的產能。顯然,我們規劃的一些製造改善不只是良率而已。更重要的是與處理更大量產品的能力相關。我過去也談過,這與我們第四代產品有關;它在研發環境中進展相當順利,現在也正進入生產設施的某些區域。
Shawn Fitz - Analyst
Shawn Fitz - Analyst
Great. And then maybe a little bit of a housekeeping question. As we look at your new patients that you added in the quarter and then your mix of existing customers on the sensor side, what's the mix in each of those two segments versus insurance -- insurance versus self-paid?
很好。接著可能是一個例行性的問題。當我們看你們本季新增的病患,以及在感測器端既有客戶的組合時,這兩個區塊各自的組成中,保險給付與自費的比例是多少?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Yes, right now we're still running around 75% insurance, and that's edging up a little bit. It slowed down in terms of its acceleration. Obviously, if you look at where we were even three, four months ago, we've gone north more towards more reimbursement and -- but there are still some patients that are cash-pay patients, both on the STK -- obviously, there's more insurance on the new patients as it relates to the introduction to STK. We still have some patients on the sensor reorder that are cash pay. What we're trying to do is move them for their benefit. We -- when they reorder, we certainly identify as a cash-pay patient, and they may -- since we have additional insurance coverage contracts and decisions that we will get new assignment of benefits and do a benefits investigation on their behalf, and they may or may not at that point be qualified for reimbursement. But I continue to see that move in that reimbursement direction.
是的,目前我們仍大約是 75% 由保險支付,而且這個比例還在小幅上升。它在加速方面有放緩。顯然,如果你看我們甚至在三、四個月前的位置,我們已經更往北移、朝向更多的給付——但仍有一些病患是自費病患,無論是在 STK 上——顯然,隨著 STK 的導入,新病患的保險比例更高。我們在感測器再訂購上仍有一些自費病患。我們試圖為了他們的利益把他們轉過來。我們——當他們再訂購時,我們會明確辨識其為自費病患;而且他們可能——由於我們有新增的保險涵蓋合約與核定,我們會取得新的給付權益轉讓(assignment of benefits),並代表他們進行給付調查(benefits investigation),屆時他們可能符合、也可能不符合給付資格。但我持續看到這個趨勢往給付方向移動。
Shawn Fitz - Analyst
Shawn Fitz - Analyst
Okay. Okay. Great. Terry, last question, as you think about the ADA conference in June, would you care to kind of talk about what we might expect from DexCom specifically and then maybe more broadly in terms of what we might see as it relates to clinical data?
好的。好的。很棒。Terry,最後一個問題,當你想到六月的 ADA 會議時,你願不願意談談我們可以特別期待 DexCom 會有什麼,以及更廣泛地說,在臨床數據方面我們可能會看到什麼?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Well, I've got Steve glaring at me right now not to talk off track here so I'll say, certainly, we've got new booth graphics. We've got some things that I think you'll be happy with. I think in the -- and actually I was going to put it in my closing comments, which I always write so the attorneys don't get to see them until I actually say them, but I'll go ahead and give them a little heartache right now.
嗯,我現在看到 Steve 正瞪著我,提醒我不要離題,所以我就說,當然,我們有新的攤位視覺設計。我們也有一些我想你會滿意的東西。我想在——其實我原本打算放在結語裡,我一向會把結語先寫好,這樣律師在我真正說出口之前看不到,但我現在就先讓他們有點心痛吧。
No, I think there's -- you'll -- last year, if you remember, ADA was all about the ACCORD trial and trying to unravel the mystery of that trial. So CGM really didn't get its place, and, in fact, there was only really one session. Two other sessions were canceled and replaced by discussions on the ACCORD trial. This year we are certainly in the front of all of that. There are a number of sessions that are going to be talking about CGM. There's, obviously, additional analysis from the JDRF trial. We've seen some of that at different meetings leading up to this. I don't think you'll see the full JDRF one-year trial results, which also have a quality-of-life and an economic analysis. I suspect that's going to be probably later in the year, maybe EASD in the September-October time frame. But there's going to be a lot more positive information about the utilization of CGM as a tool to better manage patients' diabetes.
不,我想會有——你會看到——如果你還記得,去年 ADA 的焦點全在 ACCORD 試驗,以及試圖解開那個試驗的謎團。所以 CGM 並沒有得到它應有的位置;事實上,真正只有一個場次。另外兩個場次被取消,改成討論 ACCORD 試驗。今年我們當然站在這一切的前沿。有許多場次會談到 CGM。也有——顯然——來自 JDRF 試驗的額外分析。我們在通往這次會議的不同會議上已經看到其中一些。我不認為你會看到完整的 JDRF 一年期試驗結果,那也包含生活品質與經濟分析。我猜那可能會在今年稍晚,或許是九到十月的 EASD。但會有更多正面的資訊,談到把 CGM 作為工具來更好地管理糖尿病病患的使用方式。
And I think you're going to begin to really hear a lot more, Shawn, about the role of glycemic variability in all of diabetes. And what that means -- historically, we've treated the symptoms, but we've never really understand what the other problems are associated with glycemic variability. In fact, it was, in many ways, first recognized in the ICU by [Bree] Vandenberg and Tony [Funari] and people like that because they were looking at it from a -- both diabetes and nondiabetes population. And so now you'll see a lot more that we've got to do something other than A1c because that's really a pretty poor surrogate market.
而且我想你會開始真正聽到更多,Shawn,關於血糖變異性在整個糖尿病領域中的角色。以及那代表什麼——歷史上,我們治療的是症狀,但我們從未真正理解與血糖變異性相關的其他問題是什麼。事實上,在很多方面,它最早是在加護病房(ICU)被 [Bree] Vandenberg、Tony [Funari] 等人所注意到,因為他們是從——同時涵蓋糖尿病與非糖尿病族群——的角度在看。所以現在你會看到更多:我們必須做的不只是 A1c,因為那其實是一個相當差的替代指標。
So the new thing is how do we come up with something that makes sense on glycemic variability and methodologies in order to really -- our mantra -- stay between the lines? How do you reduce those outliers? And so CGM will get a lot of play in that environment and how best to use that -- it really true is a behavior modification tool -- and how best to use that, and it's not just about measuring glucose. It's all about behavior, as well as insulin dosing. So you'll see a lot of programs and presentations, both oral, abstracts, presentations at the booth by companies talking about where they think CGM will be in the future.
所以新的課題是:我們要如何提出一個在血糖變異性上合理的指標與方法學,才能真正——我們的口號——「維持在界線之間」?你要如何降低那些離群值?因此 CGM 在那樣的環境中會受到很多關注,以及如何最好地使用它——它確實是一個行為改變工具——以及如何最好地使用它;這不只是量測葡萄糖而已。它關乎行為,也關乎胰島素劑量調整。所以你會看到很多計畫與發表,包括口頭報告、摘要,以及在攤位上的展示,各家公司會談他們認為 CGM 未來會走向何處。
Shawn Fitz - Analyst
Shawn Fitz - Analyst
Okay. Terry, congratulations on the progress. We'll see you guys in June.
好的。Terry,恭喜你們的進展。我們六月見。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Thanks.
謝謝。
Operator
Operator
And we'll take a follow-up question from Bill Plovanic.
我們接著接受 Bill Plovanic 的追問。
Anoop - Analyst
Anoop - Analyst
Hi, Terry. You mentioned the gen-four product. Could you just give us an update on the timeline for the gen-four product?
嗨,Terry。你提到第四代產品。你能不能就第四代產品的時程給我們一個更新?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
I can't give you any update on the timeline. I will just tell you that, as I've stated before, we always believe in iterations, and so one of the benefits as we move down this pathway, all of them are linked to each other. So gen-three is linked to gen-four is linked to gen-five, and gen-five is a hospital sensor. So from that standpoint, as we get more and more information, as we're in human trials on the hospital sensor with that membrane, we're able to translate that backwards into the gen-four. Don't want to give any timelines because we keep discovering new wonderful things about it each time we go out in the field.
我無法就時程提供任何更新。我只能告訴你,如我之前所說,我們一向相信迭代式開發;因此當我們沿著這條路往下走,其中一個好處是它們彼此相互連結。所以第三代連到第四代、第四代連到第五代,而第五代是醫院用感測器。從這個角度來看,當我們獲得越來越多資訊、並且在使用那種膜材的醫院用感測器上進行人體試驗時,我們能把這些成果回推並轉化到第四代上。我不想給任何時程,因為每次我們到現場時,都會不斷發現它新的美妙之處。
Anoop - Analyst
Anoop - Analyst
Okay. Well, thank you for taking the questions, and we'll see you on Tuesday at our Diabetes and Obesity Conference.
好的。謝謝你回答問題,我們星期二在我們的糖尿病與肥胖會議上見。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
You got it, Bill.
沒問題,Bill。
Operator
Operator
(Operator instructions.) We'll take a follow-up from Thom Gunderson.
(接線員指示。)我們接受 Thom Gunderson 的追問。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
Hey, Terry, could you -- maybe you commented on this and I missed it, but I think you shipped $700,000 out of your distributors in Europe during the quarter. Does that compare to virtually nothing in Q4 or $100,000 -- $200,000 and what -- is that mostly stocking orders? I mean, this is what you have to do when you're starting up with distributors is start to go to the rest of the world and get them good inventory. But where would you say we are with that whole process?
嘿,Terry,你也許已經評論過而我漏聽了,但我想你們本季從歐洲的經銷商那邊出貨了 70 萬美元。這跟第四季幾乎沒有、或是 10 萬到 20 萬美元相比如何?那主要是鋪貨訂單嗎?我的意思是,當你開始與經銷商合作時,你必須做的就是走向世界其他地區,讓他們備有足夠的庫存。但就整個流程而言,你會說我們目前進展到哪一步了?
Steve Pacelli - CAO
Steve Pacelli - CAO
Hey, Thom, this is Steve. I'm impressed you already got that far into the 10-Q considering we just filed -- no.
嗨,Thom,我是 Steve。考量到我們才剛提交 10-Q——不。你已經看到那麼後面,我很佩服。
We didn't actually mention that on the call, but you're right. No, we don't think of our use of distributors as -- primarily as stocking distributors. In fact, we're doing it on a very limited basis. Our distributors were really -- as we've talked about before -- our DME supplier/distributor strategy, if you will, in the US is absolutely one of access to reimbursement channels that we don't otherwise have access to via -- in the case of United being the big one. But there will be a whole host, and these suppliers will be a portion of our business going forward because there are economies that we can gain from their access to much smaller, more regional payers that -- we'll never be able to contract with everyone and do business with everyone. So in many instances we'll do business with the DME suppliers a means to access smaller regional payers. Jess, is looking for the number.
我們其實沒有在電話會議上提到這點,但你說得沒錯。不,我們不把使用經銷商——主要視為備貨型經銷商。事實上,我們只在非常有限的情況下這麼做。我們的經銷商其實——如同我們之前談過的——我們在美國的 DME 供應商/經銷商策略(如果你要這麼稱呼)絕對是為了取得我們原本無法取得的給付通路,尤其是 United 這個最大的。但未來會有一整批,這些供應商將成為我們未來業務的一部分,因為透過他們接觸更小、較區域性的付款方,我們可以取得規模經濟——我們不可能和所有人簽約、和所有人做生意。所以在很多情況下,我們會透過 DME 供應商來接觸較小的區域性付款方。Jess 正在找那個數字。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Yes, but let me jus weigh in. I mean, our standard even with our distributors are drop-shipped. We really try to avoid what we call a stocking-inventory distributor at all cost, just because we need to maintain control where the product is going. So in most of our situations -- there will be those one-offs. Obviously, shipping to Europe, drop-shipping is not going to be possible from that standpoint, and we have one situation here in the US, but it does not represent a huge portion of our existing business from that standpoint.
是的,但讓我補充一下。我的意思是,即使是透過經銷商,我們的標準作法也是直運(drop-shipped)。我們真的會盡一切努力避免我們所謂的備貨/庫存型經銷商,因為我們需要維持對產品流向的控制。所以在我們大多數情況下——會有一些一次性的例外。顯然,出貨到歐洲時,從這個角度來看就不可能直運;而我們在美國也有一個案例,但就這點而言,它並不代表我們現有業務中很大的一部分。
But as Steve said, I mean, going forward we -- we'll have to deal with that, but that -- the reason we really don't want to do too much of that is, quite frankly, the regulatory requirements for us and the diligence on our end of it to ensure the adequate control of that product when it's outside of our shipping department and our warehouse just increases our cost component to maintain that good regulatory control.
但如 Steve 所說,我的意思是,往後我們——我們必須面對那種情況;但我們之所以真的不想做太多,坦白說,是因為我們的法規要求,以及我們端為了確保在產品離開我們的出貨部門與倉庫之後仍能充分控制而必須做的盡職作業,會增加我們的成本構成,以維持良好的法規管控。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
Great. Thanks for the clarification.
很好。謝謝你的說明。
Operator
Operator
And we'll take a follow-up from Mimi Pham.
接下來我們接受 Mimi Pham 的追問。
Mimi Pham - Analyst
Mimi Pham - Analyst
Hi. Just a few follow-ups. Did you give us the breakout of percent MDI and percent pumpers?
嗨。我有幾個追問。你們有提供 MDI 佔比以及使用幫浦者(pumpers)佔比的拆分嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
No, we have not. Historically, Mimi, what we said was 60/40. That's based on a annual survey that we do -- 60% pumpers, 40% MDI. We'll do that survey again in the fourth quarter.
沒有,我們尚未提供。Mimi,過去我們說是 60/40。這是基於我們每年做的一項年度調查——60% 使用幫浦,40% 為 MDI。我們會在第四季再做一次該調查。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay.
好的。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
That is not something that we collect when we capture the information in terms of their insurance benefits but that's -- and other than that, there's real -- no methodology to collect it.
那不是我們在蒐集他們保險給付資訊時會一併收集的項目;除此之外,也真的——沒有方法可以蒐集。
The only other thing I can tell you is that in all of our clinical trials that we do, we don't specify what route of insulin administration is required, and so I would say in that we're about 50/50 in terms of MDI versus pump in our clinical trials. So it's somewhere in that mix between 40/60 and 50/50.
我唯一還能補充的是,在我們進行的所有臨床試驗中,我們不會指定必須採用哪一種胰島素給藥途徑,因此我會說在臨床試驗中,MDI 與幫浦大約是 50/50。所以大概落在 40/60 到 50/50 之間的某個組合。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. And are you currently in any discussions to integrate your device with any other pump manufacturers?
好的。那你們目前是否正在與其他幫浦製造商討論將你們的裝置進行整合?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
I couldn't comment on that.
我無法評論。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. And then last, do you anticipate once second half of the year, when you get through this bottleneck in processing the reimbursements, do you envision any other bottlenecks to get through your pipeline of patients?
好的。最後,你們是否預期在今年下半年,一旦你們度過這個理賠處理的瓶頸後,為了讓病患管線順利推進,還會遇到其他瓶頸嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Let me, if I may, make a clarifying statement. I don't consider it a bottleneck right now. I do consider it an opportunity to become more efficient. Bottleneck is what we did have in Q3 '08. That's not what we're experiencing today. We just have high demand and, therefore, high processing efforts being done. But we have streamlined that system. The goal is to make it even more efficient by moving from manual to electronic. So I expect that, as each module comes online, that we will continue to get much more efficient than we are today.
如果可以的話,讓我做個澄清。我不認為目前是瓶頸。我認為這是一個提升效率的機會。瓶頸是我們在 2008 年第三季確實遇到的狀況;那不是我們今天正在經歷的。我們只是需求很高,因此需要投入大量處理作業。但我們已經把那套系統精簡化。目標是透過從人工轉為電子化,讓它更有效率。所以我預期,隨著各個模組上線,我們會持續變得比現在更有效率。
The goal is to ultimately either cap or reduce the headcount in the requirements for processing higher numbers of patients with fewer bodies or on a per-submission basis. But that's -- we've got that planned out quite eloquently so we have -- I think, from a standpoint of understanding what the sizing requirements are, we've done a very good job of understanding that.
最終目標是,在以更少人力、或以每件申請(submission)為基礎的情況下,處理更多病患時,能夠把人力需求封頂或降低。但——我們已經把這件事規劃得相當周全,所以——我認為就了解規模需求而言,我們做得非常好。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. Thank you for the clarification.
好的。謝謝你的澄清。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Okay.
好的。
Operator
Operator
And there are no further questions at this time.
目前沒有其他問題。
Mr. Gregg, I'll turn things back to you for any additional or closing remarks.
Gregg 先生,我把時間交還給您,看看是否有任何補充或結語。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Operator, thank you.
接線生,謝謝你。
And for those of you still on the call, on behalf of DexCom, appreciate you tuning in, and we will update you on second quarter as we get through it. I welcome all of you to join us at ADA. I think you'll find that meeting to be very informative on the progress of CGM as a category. Thank you.
各位仍在線上的朋友,我代表 DexCom,感謝各位收聽;我們會在第二季進行期間向各位更新。我也歡迎各位在 ADA 與我們相見。我想你們會發現那場會議對於 CGM 作為一個品類的進展非常有資訊量。謝謝。
Operator
Operator
Again, thank you for participation -- for your participation. That does conclude today's conference.
再次感謝各位參與——感謝各位的參與。今天的電話會議到此結束。